Section 7: Post Congress additions最新文献_第5页

4CPS-050 Use of galcanezumab in patients with migraine in a tertiary hospital: health results galcanezumab在三级医院偏头痛患者中的应用:健康结果

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.386

A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo

引用次数: 0

6ER-013 Analysis of patients’ mortality in SARS-CoV-2 infection during the first month of hospital admission 6ER-013 SARS-CoV-2感染患者入院第一个月死亡率分析

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.431

R. Castillejo, J. Cordero, M. Romero-González, A. Martinez-Suarez

{"title":"6ER-013 Analysis of patients’ mortality in SARS-CoV-2 infection during the first month of hospital admission","authors":"R. Castillejo, J. Cordero, M. Romero-González, A. Martinez-Suarez","doi":"10.1136/ejhpharm-2022-eahp.431","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.431","url":null,"abstract":"Background and importanceAs of December 2019, the world is facing a pandemic caused by the SARS-CoV-2 coronavirus (COVID-19). Symptoms resulting from the infection vary widely, ranging from asymptomatic disease to pneumonia and life-threatening complications.Aim and objectivesThe aim was to study the impact of the active oncohaematological process on the severity and short-medium term mortality of COVID-19 infection.Material and methodsObservational retrospective study, carried out in a Spanish tertiary-level hospital. All patients diagnosed with COVID-19 and hospital admission between March 2020 and June 2021 were included. Variables collected were demographics, comorbidities;situation during hospitalisation (defining severe situation as admission to intensive care unit (ICU) or intubation) and mortality at 14 and 30 days after hospital admission. Data were obtained through the digital medical record and managed by R software (V.4–2021).ResultsWe included 1924 patients in the non-oncological group, 47.5% (915) men with a median age of 67 years and interquartile range (IQR) of 53–77. 128 patients (6.23%) were included in the active oncohaematological group, 58.6% were men (median age 72 (IQR 63–78) years). The most prevalent oncohaematological processes were: lung cancer (16.4%), colorectal (15.6%), bladder (10.9%), breast (10.2%) and prostate (8.59%). Metastases were present in 42.2% of patients. The main comorbidities presented by oncohaematological patients with statistical significance versus non-oncological patients were diabetes mellitus (30.5% vs 19.4%), dyslipidaemia (46.9% vs 32.2%), hypertension (52.3% vs 42.0%), chronic renal failure (18.0% vs 8.73%), chronic obstructive pulmonary disease (22.7% vs 9.94%), obesity (14.1% vs 15.2%) and heart failure (13.3% vs 10.6%). In the oncohaematological group, 44.5% were in a serious condition during their admission. The number who died compared to non-oncohaematological patients was 23.4% versus 13.6% at day 14 and 29.7% versus 18.1% at day 30. The two main neoplasms in the deceased patients were lung cancer (26.3%) and colorectal cancer (21%). Univariate analysis showed a relative risk of 1.72 (1.23–2.4) and 1.64 (1.23–2.17) mortality at 14 and 30 days, respectively, for COVID-19 in patients with active oncohematological processes versus non-oncohematological processes.Conclusion and relevanceThe data reflect a higher mortality at 14 and 30 days due to COVID-19 in the oncohaematological population (72% and 64%, respectively). The oncohaematological population has a higher percentage of comorbidities associated with the total that may also influence this increased risk of mortality.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114827732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

4CPS-255 Frequency of consumption of complementary and alternative medicine among HIV patients: a multicentre cross-sectional study 艾滋病患者使用补充和替代药物的频率:一项多中心横断面研究

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.412

E. Gonzalez Colominas, M. De Antonio Cuscó, M. Masip Torne, M. Martin, G. Cardona, M. Comas, Mathieu Roch, B. Lopez, FI Torres, A. Retamero, P. Luque

引用次数: 0

5PSQ-071 Real-world results of effectiveness and security of erenumab and galcanezumab in migraine patients erenumab和galcanezumab在偏头痛患者中的有效性和安全性的实际结果

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.421

A. Gracia Moya, C. Varon Galcera, I. Cardona Pascual, E. Florensa Royo, J. Vidal Otero, G. Vancells Lujan, M. G. Gorgas Torner

引用次数: 0

4CPS-022 To vaccinate or not to vaccinate: impact of a public health action on vaccine hesitancy 接种或不接种:公共卫生行动对疫苗犹豫的影响

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.380

Y. Dhif, P. Bonnabry, A. Diana

{"title":"4CPS-022 To vaccinate or not to vaccinate: impact of a public health action on vaccine hesitancy","authors":"Y. Dhif, P. Bonnabry, A. Diana","doi":"10.1136/ejhpharm-2022-eahp.380","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.380","url":null,"abstract":"Background and importanceVaccine hesitancy is one of the top 10 threats to global health according to the World Health Organization.1 A part of the Swiss population is hesitant to vaccinate against COVID-19.2Aim and objectivesThe aim of this study was to conduct a public health action with hesitant to vaccination and measure its impact on vaccine hesitancy and on vaccination rate.Material and methodsVaccine hesitancy and barriers to vaccination were measured and identified using a pre-test questionnaire. Only non-vaccinated volunteer participants were included, and they were invited to a 1-hour online session using motivational interviewing techniques, animated by a physician and a pharmacist. Two weeks after the session, they were asked to fill a post-test and 2 months later, their vaccine status was requested. Data collection was conducted from April to August 2021.Results31 adults participated for a total of 11 online sessions (2.8 participants/session). Majority were women (68%, n=21) and aged between 35 and 60 years (71%). 10 (32.3%) were public health professionals and 21 (67.7%) were not. Prior to the study, 54.9% did not consider vaccines safe (19.4% post-study), 87.1% were concerned about vaccine side effects (64.5% post-study) and 51.6% considered vaccines to be effective (83.9% post-study). Before the study, participants were classified as certainly willing to vaccinate (3.2%), probably (9.7%), probably not (35.5%), certainly not (12.9%), do not know/other (38.8%) and the degree of confidence in vaccination was 4.5 ± 2.2 (scale 1–10). After the study, the confidence increased to 6.3 ± 2.4 (+29%). Following the study, 52% (n=14) were effectively vaccinated. Among reasons that motivated to vaccinate: vaccination will help with containing the pandemic (5/14) and benefit-risk ratio is positive for the vaccine (5/14). 48% (n=13) were not vaccinated mainly for the following reasons: doubt about the effectiveness (2/13) and fear of side effects (2/13). Opinion on vaccines was moved mainly by having personal questions answered and feeling not judged for having a different opinion on vaccination.Conclusion and relevanceIn this study we could reduce vaccine hesitancy by increasing the degree of confidence in the vaccine and our action effectively convinced half the participants to get vaccinated.References and/or acknowledgements1. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-20192. https://sotomo.ch/site/wp-content/uploads/2021/02/6.-SRG-Corona-Monitor.pdfConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130986035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

4CPS-130 Analysis of the different cardioversion strategies in the emergency department in a secondary hospital 4CPS-130某二级医院急诊不同复律策略分析

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.396

R. Rodríguez Mauriz, L. Borràs Trias, N. García Farre, N. Almendros-Abad, N. Rudi Sola

引用次数: 0

4CPS-032 How to improve the appropriate prescription of anticoagulants during unexpected emergency room admittance to the hospital? A case series report using pharmacy practitioners 如何提高意外急诊入院时抗凝血药物处方的适宜性?使用药房从业人员的病例系列报告

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.384

S. Coenradie, C. Batenburg, M. De Graaf-Van Der Kort, P. Langendijk

{"title":"4CPS-032 How to improve the appropriate prescription of anticoagulants during unexpected emergency room admittance to the hospital? A case series report using pharmacy practitioners","authors":"S. Coenradie, C. Batenburg, M. De Graaf-Van Der Kort, P. Langendijk","doi":"10.1136/ejhpharm-2022-eahp.384","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.384","url":null,"abstract":"Background and importance Serious medication errors can be made during unexpected hospital admittance through the emergency ward. In particular, anticoagulants portray a great risk for patients when proper medication reconciliation is absent.We started using pharmacy practitioners (PPs) to improve this process on the emergency ward. We report here the results of two case series with respect to accuracy in the medication reconciliation on the emergency room (ER) ward. Aim and objectives To investigate if appropriate embedding of PPs in the process of medication reconciliation during unexpected admittance to the hospital could lead to fewer medication errors downstream in other hospital wards. Material and methods A PP was embedded in the ER ward team during office hours (08:00 to 17:00) to perform the medication reconciliation of unexpectedly admitted patients instead of ER physicians. The two case series of admitted patients were chosen in a post-propter design. As a zero measurement, a case series of patients (ZMCS) in a pilot phase was used (October-December 2019). This pilot phase was done to collect data on hospital administration in order to show that PPs could be embedded to do this task. This retrospective dataset consisted of 40 patients, unexpectedly admitted on the ER ward and for whom the ER physicians performed the medication reconciliation. A prospective case series of patients was then performed during the period October-December 2020 under the same conditions and used as the experimental case series (EXCS) to compare with the ZMCS. The number of medication errors in the EXCS divided by the number of medication errors during the ZMCS was our main outcome parameter expressed as a percentage. After ER admittance patients were transmitted to several other specialist wards. Results Our results showed a 40% reduction in medication errors downstream in the specialist wards when the PPs were involved in the medication reconciliation process in the EXCS compared to the medication reconciliation done by ER physicians in the ZMCS. Conclusion and relevance We conclude that PPs can make a valuable contribution to reduce the number of medication errors downstream in the hospital when embedded in the ER ward team.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131564704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

4CPS-025 Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab 利妥昔单抗治疗患者乙肝再活化预防的充分性

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.381

I. Patier, N. Herranz-Muñoz, F. Fernandez Fraga, J. Sánchez-Rubio Ferrández, I. García-Bermejo, M. Moreno-García, T. Molina-García

引用次数: 0

4CPS-126 Real-world persistence with fampridine among multiple sclerosis patients 4CPS-126多发性硬化症患者使用福普定的现实世界持久性

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.394

N. Herranz-Muñoz, J. Sánchez-Rubio Ferrández, L. Martín-Zaragoza, M. Gómez-Bermejo, S. Solís-Cuñado, T. Molina-García

引用次数: 0

4CPS-164 Durability of oral dual antiretroviral therapy in HIV patients HIV患者口服双重抗逆转录病毒治疗的持久性

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.400

L. Perez Cordon, A. Sánchez Ulayar, S. Marín Rubio, V. Aguilera Jimenez, L. Campins Bernadàs, J. Delgado Rodríguez, M. Bitlloch Obiols, R. Merino Méndez, T. Gurrera Roig, D. López Faixó

引用次数: 1